Keap calm, and carry on covalently

Journal of Medicinal Chemistry

Volumn 56, Issue 19, 2013, Pages 7463-7476

  Wilson, Anthony J ^a   Kerns, Jeffrey K ^b   Callahan, James F ^b   Moody, Christopher J ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 NAPHTHOQUINONE; 3 INDOLYLMETHYL ISOTHIOCYANATE; 4 HYDROXYNONENAL; AFATANIB; ALLYL ISOTHIOCYANATE; BARDOXOLONE METHYL; BELORANIB; BENZYL ISOTHIOCYANATE; CLOPIDOGREL; CURCUMIN; CYSTEINE; EBSELEN; ELECTROPHILE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FUMARIC ACID DIMETHYL ESTER; GLUCOBRASSICIN; GLUCONASTURTIIN; GLUCORAPHANIN; GLUCOTROPAEOLIN; ISOTHIOCYANIC ACID DERIVATIVE; KELCH LIKE ECH ASSOCIATED PROTEIN 1; NATURAL PRODUCT; OLEANOLIC ACID; OMEPRAZOLE; PHENETHYL ISOTHIOCYANATE; PLANT EXTRACT; SINIGRIN; SULFORAPHANE; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADVANCED CANCER; ANTIOXIDANT ACTIVITY; ASTHMA; BINDING AFFINITY; CANCER PREVENTION; CELL NUCLEUS; CHRONIC KIDNEY DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COVALENT BOND; CRYSTAL STRUCTURE; DIABETIC NEPHROPATHY; DISABILITY; DRUG SYNTHESIS; FOOD INTAKE; GENE MUTATION; GENETIC TRANSCRIPTION; GLOMERULUS FILTRATION RATE; HUMAN; IC 50; INFLAMMATION; LYMPHOMA; MEDICINAL PLANT; MULTIPLE SCLEROSIS; NONHUMAN; PARKINSON DISEASE; PROTEIN BINDING; PROTEIN MODIFICATION; PROTEIN MOTIF; PROTEIN STRUCTURE; PROTEIN TRANSPORT; REVIEW; SOLID TUMOR; TREATMENT OUTCOME;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; CELL NUCLEUS; DRUG DISCOVERY; ESTERS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; ISOTHIOCYANATES; KETONES; NF-E2-RELATED FACTOR 2; PROTEIN BINDING; PROTEIN CONFORMATION; SULFOXIDES;

EID: 84885603664     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400224q     Document Type: Review

References (139)

1. Itoh, K.; Chiba, T.; Takahashi, S.; Ishii, T.; Igarashi, K.; Katoh, Y.; Oyake, T.; Hayashi, N.; Satoh, K.; Hatayama, I.; Yamamoto, M.; Nabeshima, Y.-I. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements Biochem. Biophys. Res. Commun. 1997, 236, 313-322
2. Sun, J. Y.; Hoshino, H.; Takaku, K.; Nakajima, O.; Muto, A.; Suzuki, H.; Tashiro, S.; Takahashi, S.; Shibahara, S.; Alam, J.; Taketo, M. M.; Yamamoto, M.; Igarashi, K. Hemoprotein Bach1 regulates enhancer availability of heme oxygenase-1 gene EMBO J. 2002, 21, 5216-5224
3. Reichard, J. F.; Motz, G. T.; Puga, A. Heme oxygenase-1 induction by Nrf2 requires inactivation of the transcriptional repressor Bach1 Nucleic Acids Res. 2007, 35, 7074-7086
4. Jyrkkanen, H.-K.; Kuosmanen, S.; Heinaeniemi, M.; Laitinen, H.; Kansanen, E.; Mella-Aho, E.; Leinonen, H.; Yla-Herttuala, S.; Levonen, A.-L. Novel insights into the regulation of antioxidant-response-element-mediated gene expression by electrophiles: induction of the transcriptional repressor Bach1 by Nrf2 Biochem. J. 2011, 440, 167-174
5. Sun, Z.; Zhang, S.; Chan, J. Y.; Zhang, D. D. Keap1 controls postinduction repression of the Nrf2-mediated antioxidant response by escorting nuclear export of Nrf2 Mol. Cell. Biol. 2007, 27, 6334-6349
6. McMahon, M.; Thomas, N.; Itoh, K.; Yamamoto, M.; Hayes, J. D. Redox-regulated turnover of Nrf2 is determined by at least two separate protein domains, the redox-sensitive Neh2 degron and the redox-insensitive Neh6 degron J. Biol. Chem. 2004, 279, 31556-31567
7. Dinkova-Kostova, A. T.; Holtzclaw, W. D.; Cole, R. N.; Itoh, K.; Wakabayashi, N.; Katoh, Y.; Yamamoto, M.; Talalay, P. Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 11908-11913
8. Zhang, D. D.; Hannink, M. Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress Mol. Cell. Biol. 2003, 23, 8137-8151
9. Luo, Y.; Eggler, A. L.; Liu, D.; Liu, G.; Mesecar, A. D.; van Breemen, R. B. Sites of alkylation of human Keap1 by natural chemoprevention agents J. Am. Soc. Mass Spectrom. 2007, 18, 2226-2232
10. Sekhar, K. R.; Rachakonda, G.; Freeman, M. L. Cysteine-based regulation of the Cul3 adaptor protein Keap1 Toxicol. Appl. Pharmacol. 2010, 244, 21-26
11. Zipper, L. M.; Mulcahy, R. T. The Keap1 BTB/POZ dimerization function is required to sequester Nrf2 in cytoplasm J. Biol. Chem. 2002, 277, 36544-36552
12. Ogura, T.; Tong, K. I.; Mio, K.; Maruyama, Y.; Kurokawa, H.; Sato, C.; Yamamoto, M. Keap1 is a forked-stem dimer structure with two large spheres enclosing the intervening, double glycine repeat, and C-terminal domains Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 2842-2847
13. Cullinan, S. B.; Gordan, J. D.; Jin, J.; Harper, J. W.; Diehl, J. A. The Keap1-BTB protein is an adaptor that bridges Nrf2 to a Cul3-based E3 ligase: oxidative stress sensing by a Cul3-Keap1 ligase Mol. Cell. Biol. 2004, 24, 8477-8486
14. Canning, P.; Cooper, C. D. O.; Krojer, T.; Murray, J. W.; Pike, A. C. W.; Chaikuad, A.; Keates, T.; Thangaratnarajah, C.; Hojzan, V.; Marsden, B. D.; Gileadi, O.; Knapp, S.; von Delft, F.; Bullock, A. N. Structural basis for Cul3 protein assembly with the BTB-Kelch family of E3 ubiquitin ligases J. Biol. Chem. 2013, 288, 7803-7814
15. Tong, K. I.; Katoh, Y.; Kusunoki, H.; Itoh, K.; Tanaka, T.; Yamamoto, M. Keap1 recruits Neh2 through binding to ETGE and DLG motifs: characterization of the two-site molecular recognition model Mol. Cell. Biol. 2006, 26, 2887-2900
16. Tong, K. I.; Padmanabhan, B.; Kobayashi, A.; Shang, C.; Hirotsu, Y.; Yokoyama, S.; Yamamoto, M. Different electrostatic potentials define ETGE and DLG motifs as hinge and latch in oxidative stress response Mol. Cell. Biol. 2007, 27, 7511-7521
17. Zhang, D. D.; Lo, S. C.; Cross, J. V.; Templeton, D. J.; Hannink, M. Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex Mol. Cell. Biol. 2004, 24, 10941-10953
18. Padmanabhan, B.; Tong, K. I.; Ohta, T.; Nakamura, Y.; Scharlock, M.; Ohtsuji, M.; Kang, M. I.; Kobayashi, A.; Yokoyama, S.; Yamamoto, M. Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer Mol. Cell 2006, 21, 689-700
19. Li, X. C.; Zhang, D.; Hannink, M.; Beamer, L. J. Crystal structure of the Kelch domain of human Keap1 J. Biol. Chem. 2004, 279, 54750-54758
20. Eggler, A. L.; Small, E.; Hannink, M.; Mesecar, A. D. Cul3-mediated Nrf2 ubiquitination and antioxidant response element (ARE) activation are dependent on the partial molar volume at position 151 of Keap1 Biochem. J. 2009, 422, 171-180
21. Blagg, J. Structural Alerts for Toxicity. In Burger's Medicinal Chemistry, Drug Discovery and Development; Wiley: Hoboken, NJ, 2010; pp 1-34.
22. Johansson, M. H. Reversible Michael additions: Covalent inhibitors and prodrugs Mini-Rev. Med. Chem. 2012, 12, 1330-1344
23. Serafimova, I. M.; Pufall, M. A.; Krishnan, S.; Duda, K.; Cohen, M. S.; Maglathlin, R. L.; McFarland, J. M.; Miller, R. M.; Frodin, M.; Taunton, J. Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles Nat. Chem. Biol. 2012, 8, 471-476
24. Robertson, J. G. Mechanistic basis of enzyme-targeted drugs Biochemistry 2005, 44, 5561-5571
25. Guterman, L. Covalent drugs form long-lived ties Chem. Eng. News 2011, 89 (Sep 5) 19-26
26. Gersch, M.; Kreuzer, J.; Sieber, S. A. Electrophilic natural products and their biological targets Nat. Prod. Rep. 2012, 29, 659-682
27. Singh, J.; Petter, R. C.; Baillie, T. A.; Whitty, A. The resurgence of covalent drugs Nat. Rev. Drug Discovery 2011, 10, 307-317
28. Barf, T.; Kaptein, A. Irreversible protein kinase inhibitors: balancing the benefits and risks J. Med. Chem. 2012, 55, 6243-6262
29. Uruno, A.; Motohashi, H. The Keap1-Nrf2 system as an in vivo sensor for electrophiles Nitric Oxide 2011, 25, 153-160
30. Schmidt, T. J.; Ak, M.; Mrowietz, U. Reactivity of dimethyl fumarate and methyl hydrogen fumarate towards glutathione and N -acetyl- l -cysteine: preparation of S-substituted thiosuccinic acid esters Bioorg. Med. Chem. 2007, 15, 333-342
31. Linker, R. A.; Lee, D. H.; Ryan, S.; van Dam, A. M.; Conrad, R.; Bista, P.; Zeng, W.; Hronowsky, X.; Buko, A.; Chollate, S.; Ellrichmann, G.; Brück, W.; Dawson, K.; Goelz, S.; Wiese, S.; Scannevin, R. H.; Lukashev, M.; Gold, R. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway Brain 2011, 134, 678-692
32. Takaya, K.; Suzuki, T.; Motohashi, H.; Onodera, K.; Satomi, S.; Kensler, T. W.; Yamamoto, M. Validation of the multiple sensor mechanism of the Keap1-Nrf2 system Free Radical Biol. Med. 2012, 53, 817-827
33. Kaidery, N. A.; Banerjee, R.; Yang, L.; Smirnova, N. A.; Hushpulian, D. M.; Liby, K. T.; Williams, C. R.; Yamamoto, M.; Kensler, T. W.; Ratan, R. R.; Sporn, M. B.; Beal, M. F.; Gazaryan, I. G.; Thomas, B. Targeting Nrf2-mediated gene transcription by extremely potent synthetic triterpenoids attenuate dopaminergic neurotoxicity in the MPTP mouse model of Parkinson's disease Antioxid. Redox Signaling 2013, 18, 139-157
34. Liu, G. W.; Eggler, A. L.; Dietz, B. M.; Mesecar, A. D.; Bolton, J. L.; Pezzuto, J. M.; van Breemen, R. B. Screening method for the discovery of potential cancer chemoprevention agents based on mass spectrometric detection of alkylated Keap1 Anal. Chem. 2005, 77, 6407-6414
35. Hu, C.; Nikolic, D.; Eggler, A. L.; Mesecar, A. D.; van Breemen, R. B. Screening for natural chemoprevention agents that modify human Keapl Anal. Biochem. 2012, 421, 108-114
36. Kumar, V.; Kumar, S.; Hassan, M.; Wu, H.; Thimmulappa, R. K.; Kumar, A.; Sharma, S. K.; Parmar, V. S.; Biswal, S.; Malhotra, S. V. Novel chalcone derivatives as potent Nrf2 activators in mice and human lung epithelial cells J. Med. Chem. 2011, 54, 4147-4159
37. Wu, K. C.; McDonald, P. R.; Liu, J. J.; Chaguturu, R.; Klaassen, C. D. Implementation of a high-throughput screen for identifying small molecules to activate the Keap1-Nrf2-ARE pathway PLoS One 2012, 7, e44686
38. Dinkova-Kostova, A. T.; Talalay, P.; Sharkey, J.; Zhang, Y.; Holtzclaw, W. D.; Wang, X. J.; David, E.; Schiavoni, K. H.; Finlayson, S.; Mierke, D. F.; Honda, T. An exceptionally potent inducer of cytoprotective enzymes elucidation of the structural features that determine inducer potency and reactivity with Keap1 J. Biol. Chem. 2010, 285, 33747-33755
39. Sawle, P.; Moulton, B. E.; Jarzykowska, M.; Green, C. J.; Foresti, R.; Fairlamb, I. J. S.; Motterlini, R. Structure-activity relationships of methoxychalcones as inducers of heme oxygenase-1 Chem. Res. Toxicol. 2008, 21, 1484-1494
40. Dinkova-Kostova, A. T.; Liby, K. T.; Stephenson, K. K.; Holtzclaw, W. D.; Gao, X. Q.; Suh, N.; Williarrli, C.; Risingsong, R.; Honda, T.; Gribble, G. W.; Sporn, M. B.; Talalay, P. Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 4584-4589
41. Kansanen, E.; Jyrkkanen, H.-K.; Volger, O. L.; Leinonen, H.; Kivela, A. M.; Hakkinen, S.-K.; Woodcock, S. R.; Schopfer, F. J.; Horrevoets, A. J.; Yla-Herttuala, S.; Freeman, B. A.; Levonen, A.-L. Nrf2-dependent and -independent responses to nitro-fatty acids in human endothelial cells identification of heat shock response as the major pathway activated by nitro-oleic acid J. Biol. Chem. 2009, 284, 33233-33241
42. Xie, W.; Pao, C.; Graham, T.; Dul, E.; Lu, Q.; Sweitzer, T. D.; Ames, R. S.; Li, H. Development of a cell-based high throughput luciferase enzyme fragment complementation assay to identify nuclear-factor-E2-related transcription factor 2 activators Assay Drug Dev. Technol. 2012, 10, 514-524
43. Honda, T.; Dinkova-Kostova, A. T.; David, E.; Padegimas, E. M.; Sundararajan, C.; Visnick, M.; Bumeister, R.; Wigley, W. C. Synthesis and biological evaluation of 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]-4- ethynylimidazole. A novel and highly potent anti-inflammatory and cytoprotective agent Bioorg. Med. Chem. Lett. 2011, 21, 2188-2191
44. Hu, L.; Magesh, S.; Chen, L.; Wang, L.; Lewis, T. A.; Chen, Y.; Khodier, C.; Inoyama, D.; Beamer, L. J.; Emge, T. J.; Shen, J.; Kerrigan, J. E.; Kong, A.-N. T.; Dandapani, S.; Palmer, M.; Schreiber, S. L.; Munoz, B. Discovery of a small-molecule inhibitor and cellular probe of Keap1-Nrf2 protein-protein interaction Bioorg. Med. Chem. Lett. 2013, 23, 3039-3043
45. Inoyama, D.; Chen, Y.; Huang, X.; Beamer, L. J.; Kong, A.-N. T.; Hu, L. Optimization of fluorescently labeled Nrf2 peptide probes and the development of a fluorescence polarization assay for the discovery of inhibitors of Keap1-Nrf2 interaction J. Biomol. Screening 2012, 17, 435-447
46. Herr, I.; Büchler, M. W. Dietary constituents of broccoli and other cruciferous vegetables: Implications for prevention and therapy of cancer Cancer Treat. Rev. 2010, 36, 377-383
47. Zhang, Y.; Talalay, P.; Cho, C. G.; Posner, G. H. A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of structure Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 2399-2403
48. Latté, K. P.; Appel, K.-E.; Lampen, A. Health benefits and possible risks of broccoli. An overview Food Chem. Toxicol. 2011, 49, 3287-3309
49. "Huge rise" in superfood sales. http://news.bbc.co.uk/1/hi/uk/ 6736755.stm (accessed Sep 16, 2012).
50. Shikita, M.; Fahey, J. W.; Golden, T. R.; Holtzclaw, W. D.; Talalay, P. An unusual case of "uncompetitive activation" by ascorbic acid: purification and kinetic properties of a myrosinase from Raphanus sativus seedlings Biochem. J. 1999, 341, 725-732
51. Gimsing, A.; Kirkegaard, J. Glucosinolates and biofumigation: fate of glucosinolates and their hydrolysis products in soil Phytochem. Rev. 2009, 8, 299-310
52. Halkier, B. A.; Gershenzon, J. Biology and biochemistry of glucosinolates Annu. Rev. Plant Biol. 2006, 57, 303-333
53. Depree, J. A.; Howard, T. M.; Savage, G. P. Flavour and pharmaceutical properties of the volatile sulphur compounds of wasabi (Wasabia japonica) Food Res. Int. 1998, 31, 329-337
54. Tang, C.-S. Benzyl isothiocyanate of papaya fruit Phytochemistry 1971, 10, 117-121
55. Vanetten, C. H.; Daxenbichler, M. E.; Williams, P. H.; Kwolek, W. F. Glucosinolates and derived products in cruciferous vegetables-analysis of edible part from 22 varieties of cabbage J. Agric. Food Chem. 1976, 24, 452-455
56. Kassie, F.; Pool-Zobel, B.; Parzefall, W.; Knasmüller, S. Genotoxic effects of benzyl isothiocyanate, a natural chemopreventive agent Mutagenesis 1999, 14, 595-604
57. Cheung, K.; Kong, A.-N. Molecular targets of dietary phenethyl isothiocyanate and sulforaphane for cancer chemoprevention AAPS J. 2010, 12, 87-97
58. Pawlik, A.; Szczepanski, M. A.; Klimaszewska, A.; Gackowska, L.; Zuryn, A.; Grzanka, A. Phenethyl isothiocyanate-induced cytoskeletal changes and cell death in lung cancer cells Food Chem. Toxicol. 2012, 50, 3577-3594
59. Satyan, K. S.; Swamy, N.; Dizon, D. S.; Singh, R.; Granai, C. O.; Brard, L. Phenethyl isothiocyanate (PEITC) inhibits growth of ovarian cancer cells by inducing apoptosis: role of caspase and MAPK activation Gynecol. Oncol. 2006, 103, 261-270
60. Xiao, D.; Powolny, A. A.; Moura, M. B.; Kelley, E. E.; Bommareddy, A.; Kim, S.-H.; Hahm, E. R.; Normolle, D.; Houten, V. V.; Singh, S. V. Phenethyl isothiocyanate inhibits oxidative phosphorylation to trigger reactive oxygen species-mediated death of human prostate cancer cells J. Biol. Chem. 2010, 285, 26558-26569
61. Agerbirk, N.; De Vos, M.; Kim, J.; Jander, G. Indole glucosinolate breakdown and its biological effects Phytochem. Rev. 2009, 8, 101-120
62. Galan, M. V.; Kishan, A. A.; Silverman, A. L. Oral broccoli sprouts for the treatment of Helicobacter pylori infection: a preliminary report Dig. Dis. Sci. 2004, 49, 1088-1090
63. Yanaka, A.; Fahey, J. W.; Fukumoto, A.; Nakayama, M.; Inoue, S.; Zhang, S.; Tauchi, M.; Suzuki, H.; Hyodo, I.; Yamamoto, M. Dietary sulforaphane-rich broccoli sprouts reduce colonization and attenuate gastritis in Helicobacter pylori infected mice and humans Cancer Prev. Res. 2009, 2, 353-360
64. Fahey, J. W.; Haristoy, X.; Dolan, P. M.; Kensler, T. W.; Scholtus, I.; Stephenson, K. K.; Talalay, P.; Lozniewski, A. Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzo[ a ]pyrene-induced stomach tumors Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 7610-7615
65. Guerrero-Beltrán, C. E.; Calderón-Oliver, M.; Pedraza-Chaverri, J.; Chirino, Y. I. Protective effect of sulforaphane against oxidative stress: recent advances Exp. Toxicol. Pathol. 2012, 64, 503-508
66. Li, Y.; Zhang, T.; Korkaya, H.; Liu, S.; Lee, H.-F.; Newman, B.; Yu, Y.; Clouthier, S. G.; Schwartz, S. J.; Wicha, M. S.; Sun, D. Sulforaphane, a dietary component of broccoli/broccoli sprouts, inhibits breast cancer stem cells Clin. Cancer Res. 2010, 16, 2580-2590
67. Sulforaphane in clinical trials. http://clinicaltrials.gov/ct2/results? term=Sulforaphane (accessed Sep 14, 2012).
68. Hayes, J.; Kelleher, M.; Eggleston, I. The cancer chemopreventive actions of phytochemicals derived from glucosinolates Eur. J. Nutr. 2008, 47, 73-88
69. Posner, G. H.; Cho, C. G.; Green, J. V.; Zhang, Y. S.; Talalay, P. Design and synthesis of bifunctional isothiocyanate analogs of sulforaphane- correlation between structure and potency as inducers of anticarcinogenic detoxication enzymes J. Med. Chem. 1994, 37, 170-176
70. Morimitsu, Y.; Nakagawa, Y.; Hayashi, K.; Fujii, H.; Kumagai, T.; Nakamura, Y.; Osawa, T.; Horio, F.; Itoh, K.; Iida, K.; Yamamoto, M.; Uchida, K. A sulforaphane analogue that potently activates the Nrf2-dependent detoxification pathway J. Biol. Chem. 2002, 277, 3456-3463
71. Ahn, Y.-H.; Hwang, Y.; Liu, H.; Wang, X. J.; Zhang, Y.; Stephenson, K. K.; Boronina, T. N.; Cole, R. N.; Dinkova-Kostova, A. T.; Talalay, P.; Cole, P. A. Electrophilic tuning of the chemoprotective natural product sulforaphane Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 9590-9595
72. Honda, T.; Finlay, H. J.; Gribble, G. W.; Suh, N.; Sporn, M. B. New enone derivatives of oleanolic acid and ursolic acid as inhibitors of nitric oxide production in mouse macrophages Bioorg. Med. Chem. Lett. 1997, 7, 1623-1628
73. Honda, T.; Rounds, B. V.; Gribble, G. W.; Suh, N.; Wang, Y.; Sporn, M. B. Design and synthesis of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, a novel and highly active inhibitor of nitric oxide production in mouse macrophages Bioorg. Med. Chem. Lett. 1998, 8, 2711-2714
74. Liby, K. T.; Sporn, M. B. Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease Pharmacol. Rev. 2012, 64, 972-1003
75. Sporn, M. B.; Liby, K. T.; Yore, M. M.; Fu, L.; Lopchuk, J. M.; Gribble, G. W. New synthetic triterpenoids: potent agents for prevention and treatment of tissue injury caused by inflammatory and oxidative stress J. Nat. Prod. 2011, 74, 537-545
76. Liby, K.; Hock, T.; Yore, M. M.; Suh, N.; Place, A. E.; Risingsong, R.; Williams, C. R.; Royce, D. B.; Honda, T.; Honda, Y.; Gribble, G. W.; Hill-Kapturczak, N.; Agarwal, A.; Sporn, M. B. The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling Cancer Res. 2005, 65, 4789-4798
77. Couch, R. D.; Browning, R. G.; Honda, T.; Gribble, G. W.; Wright, D. L.; Sporn, M. B.; Anderson, A. C. Studies on the reactivity of CDDO, a promising new chemopreventive and chemotherapeutic agent: implications for a molecular mechanism of action Bioorg. Med. Chem. Lett. 2005, 15, 2215-2219
78. Avonto, C.; Taglialatela-Scafati, O.; Pollastro, F.; Minassi, A.; Di Marzo, V.; De Petrocellis, L.; Appendino, G. An NMR spectroscopic method to identify and classify thiol-trapping agents: revival of Michael acceptors for drug discovery? Angew. Chem., Int. Ed. 2011, 50, 467-471
79. Honda, T.; Rounds, B. V.; Bore, L.; Finlay, H. J.; Favaloro, F. G.; Suh, N.; Wang, Y. P.; Sporn, M. B.; Gribble, G. W. Synthetic oleanane and ursane triterpenoids with modified rings A and C: a series of highly active inhibitors of nitric oxide production in mouse macrophages J. Med. Chem. 2000, 43, 4233-4246
80. Salomatina, O. V.; Logashenko, E. B.; Korchagina, D. V.; Salakhutdinov, N. F.; Zenkova, M. A.; Vlasov, V. V.; Tolstikov, G. A. Synthesis and biological activity of novel glycyrrhetic acid derivatives Dokl. Chem. 2010, 430, 35-38
81. Honda, T.; Liby, K. T.; Su, X.; Sundararajan, C.; Honda, Y.; Suh, N.; Risingsong, R.; Williams, C. R.; Royce, D. B.; Sporn, M. B.; Gribble, G. W. Design, synthesis, and anti-inflammatory activity both in vitro and in vivo of new betulinic acid analogues having an enone functionality in ring A Bioorg. Med. Chem. Lett. 2006, 16, 6306-6309
82. Honda, T.; Yoshizawa, H.; Sundararajan, C.; David, E.; Lajoie, M. J.; Favaloro, F. G., Jr.; Janosik, T.; Su, X.; Honda, Y.; Roebuck, B. D.; Gribble, G. W. Tricyclic compounds containing nonenolizable cyano enones. A novel class of highly potent anti-inflammatory and cytoprotective agents J. Med. Chem. 2011, 54, 1762-1778
83. Zheng, S.; Laxmi, Y. R. S.; David, E.; Dinkova-Kostova, A. T.; Shiavoni, K. H.; Ren, Y.; Zheng, Y.; Trevino, I.; Bumeister, R.; Ojima, I.; Wigley, W. C.; Bliska, J. B.; Mierke, D. F.; Honda, T. Synthesis, chemical reactivity as Michael acceptors, and biological potency of monocyclic cyanoenones, novel and highly potent anti-inflammatory and cytoprotective agents J. Med. Chem. 2012, 55, 4837-4846
84. Seo, J. Y.; Park, J.; Kim, H. J.; Lee, I. A.; Lim, J.-S.; Lim, S. S.; Choi, S.-J.; Park, J. H. Y.; Kang, H. J.; Kim, J.-S. Isoalantolactone from Inula helenium caused Nrf2-mediated induction of detoxifying enzymes J. Med. Food 2009, 12, 1038-1045
85. 2 Free Radical Biol. Med. 2009, 47, 1310-1317
86. Kachadourian, R.; Day, B. J.; Pugazhenti, S.; Franklin, C. C.; Genoux-Bastide, E.; Mahaffey, G.; Gauthier, C.; Di Pietro, A.; Boumendjel, A. A synthetic chalcone as a potent inducer of glutathione biosynthesis J. Med. Chem. 2012, 55, 1382-1388
87. Rossi, A.; Kapahi, P.; Natoli, G.; Takahashi, T.; Chen, Y.; Karin, M.; Santoro, M. G. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of I kappa B kinase Nature 2000, 403, 103-108
88. Lee, C.-Y.; Chew, E.-H.; Go, M.-L. Functionalized aurones as inducers of NAD(P)H:quinone oxidoreductase 1 that activate AhR/XRE and Nrf2/ARE signaling pathways: synthesis, evaluation and SAR Eur. J. Med. Chem. 2010, 45, 2957-2971
89. Ma, Q.; He, X. Molecular basis of electrophilic and oxidative defense: promises and perils of Nrf2 Pharmacol. Rev. 2012, 64, 1055-1081
90. Magesh, S.; Chen, Y.; Hu, L. Small molecule modulators of Keap1-Nrf2-ARE pathway as potential preventive and therapeutic agents Med. Res. Rev. 2012, 32, 687-726
91. Baird, L.; Dinkova-Kostova, A. T. The cytoprotective role of the Keap1-Nrf2 pathway Arch. Toxicol. 2011, 85, 241-272
92. Hur, W.; Gray, N. S. Small molecule modulators of antioxidant response pathway Curr. Opin. Chem. Biol. 2011, 15, 162-173
93. Surh, Y.-J.; Kundu, J. K.; Na, H.-K. Nrf2 as a master redox switch in turning on the cellular signaling involved in the induction of cytoprotective genes by some chemopreventive phytochemicals Planta Med. 2008, 74, 1526-1539
94. Li, X. C.; Zhang, D.; Hannink, M.; Beamer, L. J. Crystallization and initial crystallographic analysis of the Kelch domain from human Keap1 Acta Crystallogr., Sect. D 2004, 60, 2346-2348
95. Lo, S.-C.; Li, X.; Henzl, M. T.; Beamer, L. J.; Hannink, M. Structure of the Keap1: Nrf2 interface provides mechanistic insight into Nrf2 signaling EMBO J. 2006, 25, 3605-3617
96. Padmanabhan, B.; Tong, K. I.; Kobayashi, A.; Yamamoto, M.; Yokoyama, S. Structural insights into the similar modes of Nrf2 transcription factor recognition by the cytoplasmic repressor Keap1 J. Synchrotron Radiat. 2008, 15, 273-276
97. Padmanabhan, B.; Nakamura, Y.; Yokoyama, S. Structural analysis of the complex of Keap1 with a prothymosin α peptide Acta Crystallogr., Sect. F 2008, 64, 233-238
98. Kern, J. T.; Hess, J. W.; Kandpal, G.; Reynolds, I. J. Method for Identifying Modulators of the Nrf2-Keap1-ARE Pathway. WO 2008057434, 2008.
99. Hu, L.; Inoyama, D. High-Throughput Screening Fluorescence Polarization Assay for Inhibitors of Keap1-Nrf2 Interaction. US 20120202298, 2012.
100. Hancock, R.; Bertrand, H. C.; Tsujita, T.; Naz, S.; El-Bakry, A.; Laoruchupong, J.; Hayes, J. D.; Wells, G. Peptide inhibitors of the Keap1-Nrf2 protein-protein interaction Free Radical Biol. Med. 2012, 52, 444-451
101. Chen, Y.; Inoyama, D.; K., A.-N. T.; Beamer, L. J.; Hu, L. Kinetic analyses of Keap1-Nrf2 interaction and determination of the minimal Nrf2 peptide sequence required for Keap1 binding using surface plasmon resonance Chem. Biol. Drug Des. 2011, 78, 1014-1021
102. Steel, R.; Cowan, J.; Payerne, E.; O'Connell, M. A.; Searcey, M. Anti-inflammatory effect of a cell-penetrating peptide targeting the Nrf2/Keap1 interaction ACS Med. Chem. Lett. 2012, 3, 407-410
103. Marcotte, D.; Zeng, W.; Hus, J.-C.; McKenzie, A.; Hession, C.; Jin, P.; Bergeron, C.; Lugovskoy, A.; Enyedy, I.; Cuervo, H.; Wanga, D.; Atmanene, C.; Roecklin, D.; Vecchi, M.; Vivat, V.; Kraemer, J.; Winkler, D.; Hong, V.; Chao, J.; Lukashev, M.; Silvian, L. Small molecules inhibit the interaction of Nrf2 and the Keap1 Kelch domain through a non-covalent mechanism Bioorg. Med. Chem. 2013, 21, 4011-4019
104. Shimozono, R.; Asaoka, Y.; Yoshizawa, Y.; Aoki, T.; Noda, H.; Yamada, M.; Kaino, M.; Mochizuki, H. Nrf2-activators attenuate the progression of nonalcoholic steatohepatitis-related fibrosis in a dietary rat model Mol. Pharmacol. 2013, 84, 62-70
105. Sporn, M. B.; Liby, K. T. Nrf2 and cancer: the good, the bad and the importance of context Nat. Rev. Cancer 2012, 12, 564-571
106. Kensler, T. W.; Wakabayashi, N.; Biswal, S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway Annu. Rev. Pharmacol. 2007, 47, 89-116
107. Iida, K.; Itoh, K.; Kumagai, Y.; Oyasu, R.; Hattori, K.; Kawai, K.; Shimazui, T.; Akaza, H.; Yamamoto, M. Nrf2 is essential for the chemopreventive efficacy of oltipraz against urinary bladder carcinogenesis Cancer Res. 2004, 64, 6424-6431
108. Xu, C.; Huang, M. T.; Shen, G.; Yuan, X.; Lin, W.; Khor, T. O.; Conney, A. H.; Kong, A. N. T. Inhibition of 7,12-dimethylbenz[ a ]anthracene-induced skin tumorigenesis in C57BL/6 mice by sulforaphane is mediated by nuclear factor E2 related factor 2 Cancer Res. 2006, 66, 8293-8296
109. Iida, K.; Itoh, K.; Maher, J. M.; Kumagai, Y.; Oyasu, R.; Mori, Y.; Shimazui, T.; Akaza, H.; Yamamoto, M. Nrf2 and p53 cooperatively protect against BBN-induced urinary bladder carcinogenesis Carcinogenesis 2007, 28, 2398-2403
110. Higgins, L. G.; Kelleher, M. O.; Eggleston, I. M.; Itoh, K.; Yamamoto, M.; Hayes, J. D. Transcription factor Nrf2 mediates an adaptive response to sulforaphane that protects fibroblasts in vitro against the cytotoxic effects of electrophiles, peroxides and redox-cycling agents Toxicol. Appl. Pharmacol. 2009, 237, 267-280
111. Shibata, T.; Kokubu, A.; Gotoh, M.; Ojima, H.; Ohta, T.; Yamamoto, M.; Hirohashi, S. Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer Gastroenterology 2008, 135, 1358-1368
112. Taguchi, K.; Motohashi, H.; Yamamoto, M. Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution Genes Cells 2011, 16, 123-140
113. Shibata, T.; Ohta, T.; Tong, K. I.; Kokubu, A.; Odogawa, R.; Tsuta, K.; Asamura, H.; Yamamoto, M.; Hirohashi, S. Cancer related mutations in Nrf2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 13568-13573
114. Okawa, H.; Motohashi, H.; Kobayashi, A.; Aburatani, H.; Kensler, T. W.; Yamamoto, M. Hepatocyte-specific deletion of the Keap1 gene activates Nrf2 and confers potent resistance against acute drug toxicity Biochem. Biophys. Res. Commun. 2006, 339, 79-88
115. Singh, A.; Boldin-Adamsky, S.; Thimmulappa, R. K.; Rath, S. K.; Ashush, H.; Coulter, J.; Blackford, A.; Goodman, S. N.; Bunz, F.; Watson, W. H.; Gabrielson, E.; Feinstein, E.; Biswal, S. RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy Cancer Res. 2008, 68, 7975-7984
116. Singh, A.; Misra, V.; Thimmulappa, R. K.; Lee, H.; Ames, S.; Hoque, M. O.; Herman, J. G.; Baylin, S. B.; Sidransky, D.; Gabrielson, E.; Brock, M. V.; Biswal, S. Dysfunctional Keap1-Nrf2 interaction in non-small-cell lung cancer PLoS Med 2006, 3, e420
117. Wang, X. J.; Sun, Z.; Villeneuve, N. F.; Zhang, S.; Zhao, F.; Li, Y.; Chen, W.; Yi, X.; Zheng, W.; Wondrak, G. T.; Wong, P. K.; Zhang, D. D. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2 Carcinogenesis 2008, 29, 1235-1243
118. MacNee, W. Oxidants and COPD Curr. Drug Targets 2005, 4, 627-641
119. MacNee, W. Pulmonary and systemic oxidant/antioxidant imbalance in chronic obstructive pulmonary disease Proc. Am. Thorac. Soc. 2005, 2, 50-60
120. MacNee, W. Oxidative Stress and Chronic Obstructive Pulmonary Disease. In Management of Chronic Obstructive Pulmonary Disease; Siafakas, N. M., Ed.; European Respiratory Society Monograph, Vol. 38; European Respiratory Society: Sheffield, U.K., 2006; pp 100-129.
121. Adenuga, D.; Caito, S.; Yao, H.; Sundar, I. K.; Hwang, J. W.; Chung, S.; Rahman, I. Nrf2 deficiency influences susceptibility to steroid resistance via HDAC2 reduction Biochem. Biophys. Res. Commun. 2010, 403, 452-456
122. Harvey, C. J.; Thimmulappa, R. K.; Sethi, S.; Kong, X.; Yarmus, L.; Brown, R. H.; Feller-Kopman, D.; Wise, R.; Biswal, S. Targeting Nrf2 signaling improves bacterial clearance by alveolar macrophages in patients with COPD and in a mouse model Sci. Transl. Med. 2011, 3, 78ra32-78ra32
123. Goven, D.; Boutten, A.; Leáon-Malas, V.; Marchal-SommÇ, J.; Amara, N.; Crestani, B.; Fournier, M.; Lesäche, G.; Soler, P.; Boczkowski, J.; Bonay, M. Altered Nrf2/Keap1-Bach1 equilibrium in pulmonary emphysema Thorax 2008, 63, 916-924
124. Suzuki, M.; Betsuyaku, T.; Ito, Y.; Nagai, K.; Nasuhara, Y.; Kaga, K.; Kondo, S.; Nishimura, M. Down-regulated nf-E2-related factor 2 in pulmonary macrophages of aged smokers and patients with chronic obstructive pulmonary disease Am. J. Respir. Cell Mol. Biol. 2008, 39, 673-682
125. Malhotra, D.; Thimmulappa, R.; Navas-Acien, A.; Sandford, A.; Elliott, M.; Singh, A.; Chen, L.; Zhuang, X.; Hogg, J.; Pare, P.; Tuder, R. M.; Biswal, S. Decline in Nrf2-regulated antioxidants in chronic obstructive pulmonary disease lungs due to loss of its positive regulator, DJ-1 Am. J. Respir. Crit. Care Med. 2008, 178, 592-604
126. Mukherjee, S.; Gangopadhyay, H.; Das, D. K. Broccoli: a unique vegetable that protects mammalian hearts through the redox cycling of the thioredoxin superfamily J. Agric. Food Chem. 2007, 56, 609-617
127. Senanayake, G. V. K.; Banigesh, A.; Wu, L.; Lee, P.; Juurlink, B. H. J. The dietary phase 2 protein inducer sulforaphane can normalize the kidney epigenome and improve blood pressure in hypertensive rats Am. J. Hypertens. 2012, 25, 229-235
128. Wu, L.; Ashraf, M. H. N.; Facci, M.; Wang, R.; Paterson, P. G.; Ferrie, A.; Juurlink, B. H. J. Dietary approach to attenuate oxidative stress, hypertension, and inflammation in the cardiovascular system Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 7094-7099
129. Scannevin, R. H.; Chollate, S.; Jung, M. Y.; Shackett, M.; Patel, H.; Bista, P.; Zeng, W.; Ryan, S.; Yamamoto, M.; Lukashev, M.; Rhodes, K. J. Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway J. Pharmacol. Exp. Ther. 2012, 341, 274-284
130. Kappos, L.; Gold, R.; Miller, D. H.; MacManus, D. G.; Havrdova, E.; Limmroth, V.; Polman, C. H.; Schmierer, K.; Yousry, T. A.; Eraksoy, M.; Meluzinova, E.; Dufek, M.; Yang, M.; Dawson, K.; O'Neill, G. N. Effect of BG-12 on contrast-enhanced lesions in patients with relapsing-remitting multiple sclerosis: subgroup analyses from the phase 2b study Mult. Scler. 2012, 18, 314-321
131. Gold, R.; Miller, D. H.; Phillips, J. T.; Arnold, D. L.; Selmaj, K.; Yang, M.; Zhang, R.; Dawson, K. T.; Viglietta, V.; Sheikh, S. I.; Fox, R. J. Clinical Efficacy of BG-12 in Relapsing-Remitting Multiple Sclerosis: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies. Presented at the 28th Congress of the European Committee for the Treatment and Research of Multiple Sclerosis, Lyon, France, 2012.
132. Adam, J.; Hatipoglu, E.; O'Flaherty, L.; Ternette, N.; Sahgal, N.; Lockstone, H.; Baban, D.; Nye, E.; Stamp, G. W.; Wolhuter, K.; Stevens, M.; Fischer, R.; Carmeliet, P.; Maxwell, P. H.; Pugh, C. W.; Frizzell, N.; Soga, T.; Kessler, B. M.; El-Bahrawy, M.; Ratcliffe, P. J.; Pollard, P. J. Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in Keap1 succination and Nrf2 signaling Cancer Cell 2011, 20, 524-537
133. Ooi, A.; Wong, J.-C.; Petillo, D.; Roossien, D.; Perrier-Trudova, V.; Whitten, D.; Min, B. W. H.; Tan, M.-H.; Zhang, Z.; Yang, X. J.; Zhou, M.; Gardie, B.; Molinie, V.; Richard, S.; Tan, P. H.; Teh, B. T.; Furge, K. A. An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma Cancer Cell 2011, 20, 511-523
134. Fox, E. J.; Rhoades, R. W. New treatments and treatment goals for patients with relapsing-remitting multiple sclerosis Curr. Opin. Neurol. 2012, 25, S11-S19
135. Pergola, P. E.; Krauth, M.; Huff, J. W.; Ferguson, D. A.; Ruiz, S.; Meyer, C. J.; Warnock, D. G. Effect of bardoxolone methyl on kidney function in patients with T2D and stage 3b-4 CKD Am. J. Nephrol. 2011, 33, 469-476
136. Pergola, P. E.; Raskin, P.; Toto, R. D.; Meyer, C. J.; Huff, J. W.; Grossman, E. B.; Krauth, M.; Ruiz, S.; Audhya, P.; Christ-Schmidt, H.; Wittes, J.; Warnock, D. G. Bardoxolone methyl and kidney function in CKD with type 2 diabetes N. Engl. J. Med. 2011, 365, 327-336
137. Hong, D. S.; Kurzrock, R.; Supko, J. G.; He, X.; Naing, A.; Wheler, J.; Lawrence, D.; Eder, J. P.; Meyer, C. J.; Ferguson, D. A.; Mier, J.; Konopleva, M.; Konoplev, S.; Andreeff, M.; Kufe, D.; Lazarus, H.; Shapiro, G. I.; Dezube, B. J. A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas Clin. Cancer Res. 2012, 18, 3396-3406
138. Ahmad, R.; Raina, D.; Meyer, C.; Kharbanda, S.; Kufe, D. Triterpenoid CDDO-Me blocks the NF-κB pathway by direct inhibition of IKK on Cys-179 J. Biol. Chem. 2006, 281, 35764-35769
139. Tayek, J. A.; Kalantar-Zadeh, K. The extinguished BEACON of bardoxolone: not a Monday morning quarterback story Am. J. Nephrol. 2013, 37, 208-211